期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 13, 期 9, 页码 849-866出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2019.1649981
关键词
Nonalcoholic fatty liver disease; fatty liver disease; hepatology; diabetes; insulin resistance
资金
- Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [1119145, 1191183]
- Comision Nacional de Investigacion Cientifica y Tecnologica, grant CONICYT PIA/Basal, Basal Centre for Excellence in Science and Technology [PFB12]
Introduction: The relationship between nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) is complex and bidirectional. NAFLD increases the risk of incident diabetes and is very prevalent in T2DM patients and T2DM is an aggravating factor for NAFLD. Timely T2DM diagnosis and treatment in subjects with NAFLD and diagnosis, staging and treatment of NAFLD in those with T2DM are critical issues. Areas covered: PubMed/MEDLINE was searched for articles related to concomitant occurrence of NAFLD and T2DM between January 2013 and May 2019. Areas covered included epidemiological, diagnostic and therapeutic aspects. Expert opinion: there is a need for increased awareness on NAFLD adding liver disease as an end-organ complication of T2DM. Emphasis on use of simple non-invasive tools to triage patients with potentially severe liver disease should be made. Management of patients with NAFLD and T2DM relies on lifestyle optimization to achieve significant weight loss. Currently, there is no drug approved for treatment of NAFLD in patients with T2DM although Vitamin E and pioglitazone might be used in selected patients. Approved diabetic medications hold promise for NAFLD treatment and several liver-specific drugs are in evaluation clinical trials. A combination approach will likely represent the future of NAFLD therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据